Earnings Call · Q3 FY2023·2023-11-08

Q3 23EPS +2.67%·Rev n/aQ2 23EPS -7.46%·Rev n/aQ1 23EPS -5.00%·Rev n/aQ4 22EPS +1.72%·Rev n/a⚠ consensus missing

Xenon Pharmaceuticals Inc. XENE

Sherry Aulin — Chief Financial Officer

Ian Mortimer — President and Chief Executive Officer

Chris Kenney — Chief Medical Officer

Chris Von Seggern — Role not explicitly stated, likely in Market Research or Commercial Strategy

−6.7%1d on move date−5.9% vs SPY3d−7.6%5d−9.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XENE calls or request research access.

More XENE calls Browse calls Request research access